Takeda Pharmaceutical Company Limited Share Price Fukuoka Stock Exchange
Equities
4502
JP3463000004
Pharmaceuticals
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,080 JPY | -1.21% | -.--% | +2.13% |
16/05 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
15/05 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
Sales 2024 | 4,264B 27.19B 2,264B | Sales 2025 * | 4,097B 26.13B 2,175B | Capitalization | 6,436B 41.05B 3,418B |
---|---|---|---|---|---|
Net income 2024 | 144B 919M 76.51B | Net income 2025 * | 136B 866M 72.07B | EV / Sales 2024 | 1.54 x |
Net Debt 2024 * | 3,771B 24.05B 2,002B | Net Debt 2025 * | 4,204B 26.81B 2,232B | EV / Sales 2025 * | 2.6 x |
P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
45.5
x | Employees | - |
Yield 2024 * |
4.58% | Yield 2025 * |
4.65% | Free-Float | 99.12% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 month | -5.01% | ||
Current year | +2.13% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 01/14/01 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 01/22/01 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 01/12/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 01/16/01 | |
Ian Clark
BRD | Director/Board Member | 62 | 01/19/01 |
Steven Gillis
BRD | Director/Board Member | 71 | 01/19/01 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.74% | 723B | |
+32.22% | 598B | |
-2.07% | 364B | |
+20.25% | 331B | |
+2.99% | 288B | |
+16.60% | 244B | |
+9.77% | 210B | |
-5.15% | 208B | |
+7.43% | 169B |
- Stock Market
- Equities
- 4502 Stock
- 4502 Stock